UnitedHealth Group Faces Growing Pressure to Split Optum After CVS Announces 117-Billion-Dollar Breakup

The aftershocks from CVS Health's stunning decision to break itself into two companies are now rippling across the entire healthcare industry, and no company faces more scrutiny than UnitedHealth Group, the nation's largest health insurer and owner of Optum, the sprawling health services empire that touches nearly every corner of American medicine.

Just two days after CVS announced its $117 billion split on November 4, industry analysts and antitrust experts are openly questioning whether UnitedHealth will be forced to follow suit. The company's vertically integrated model—combining insurance through UnitedHealthcare with pharmacy benefits, physician practices, and surgical centers through Optum—has long drawn regulatory scrutiny. CVS's decision to unwind a similar strategy now sets a precedent that could reshape the industry.

Optum owns or employs more than 70,000 physicians across the United States, roughly 10 percent of the nation's entire physician workforce. It operates pharmacy benefit management services that process prescriptions for millions of Americans, runs urgent care clinics and surgical centers, and controls data analytics platforms that influence care decisions across the healthcare system. This level of vertical integration has made UnitedHealth extraordinarily profitable but has also made it a target for regulators concerned about market concentration.

CVS's breakup unwinds a strategy that began with the 2007 acquisition of Caremark, which handled prescription benefits, and culminated in the 2018 purchase of health insurer Aetna. The company argued that combining insurance, pharmacy benefits, and retail pharmacies would create efficiencies and improve patient outcomes. Instead, it created complexity, regulatory headaches, and mounting losses in the retail pharmacy business that ultimately forced the reversal.

For UnitedHealth, the parallels are unmistakable. The company has built Optum into a revenue-generating machine that brought in over $226 billion in 2025, dwarfing the insurance side of the business. But that growth has come with increasing political and regulatory pressure, particularly around concerns that Optum's physician practices steer patients toward services that benefit UnitedHealthcare's bottom line rather than what's best for patients.

Speculation about a forced divestiture has been building for months. In October, reports surfaced that UnitedHealth was exploring the sale of Optum's UK operations, fueling speculation that the company was preparing for a broader breakup. Regulatory experts have long argued that the only way to satisfy antitrust concerns might be a forced split between Optum and UnitedHealthcare, severing the information flows and financial incentives that critics say distort medical decision-making.

The CVS split sends a clear signal to the market: the era of healthcare mega-consolidation is over. Investors and policymakers now view vertical integration with deep skepticism, believing that the promised efficiencies rarely materialize while anticompetitive risks multiply. If CVS concluded that unwinding its empire was the best path forward, UnitedHealth may soon face the same calculation.

Optionally, UnitedHealth could choose to sell off parts of Optum rather than splitting entirely, divesting the physician practices or pharmacy benefit management operations while keeping the data analytics and technology businesses. But even that approach would represent a dramatic reversal of the company's 15-year strategy of buying up every part of the healthcare supply chain it could reach.

For now, UnitedHealth has not announced any plans to break up or sell assets. The company's stock dropped briefly after the CVS news before recovering, suggesting investors are still processing what this means for the industry's biggest player. But the pressure is building, and the CVS precedent makes it much harder for UnitedHealth to argue that its vertically integrated model is sustainable in the current regulatory environment.